The FINANCIAL -- Tokyo, Japan (September 12, 2011) – Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) today announced that some batches of its Kitasato Daiichi Sankyo influenza HA vaccine and Kitasato Daiichi Sankyo influenza HA vaccine syringe produced by its subsidiary, Kitasato Daiichi Sankyo Vaccine, did not meet criteria in a test of quality standards.

Consequently, some shipments of the two products scheduled within this month will be delayed. Daiichi Sankyo offers its deepest apologies to all healthcare professionals and other persons who are waiting for this vaccine.

Another announcement will be made about the supply of these products at a later date.

Related Stories

• New Phase 3 data for Tradjenta tablets in black or African American patients with type 2 diabetes
• Innovative public-private collaboration launches to tackle antibiotic research
• Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure